July 26th 2024
SenoVax, a novel senolytic immunotherapy for NSCLC, has been submitted as an investigational new drug application to the FDA, initiating a clinical trial to test its efficacy.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Counseling Patients on Next Steps After Chemoradiation for Stage III NSCLC
July 17th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed with participants what therapy to use, including adjuvant immunotherapy, for a patient with stage III non–small cell lung cancer. This is the second of 2 articles based on this event.
Read More
Kelly Explores Current Immunotherapy/Chemotherapy Combinations in NSCLC
July 13th 2023During a Targeted Oncology™ Clinical Case Forum™ event, Ronan J. Kelly, MD, MBA, discussed the significance of the CheckMate 9LA, KEYNOTE-407, EMPOWER-Lung 3, and POSEIDON studies which all explored immunotherapies in patients with advanced non–small cell lung cancer.
Read More
ADAURA: Overall Survival Analysis of Osimertinib in NSCLC
July 7th 2023Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).
Watch
Physicians Discuss Up-Front Options for Unresectable Stage III NSCLC
June 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed options including concurrent chemoradiation therapy and neoadjuvant therapy for a patient with stage IIIA lung adenocarcinoma.
Read More
Multidisciplinary Practice Management Is “Critical” in Lung Cancer
June 16th 2023In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed practice management strategies as a thoracic medical oncologist, including multidisciplinary care, communication between inpatient and outpatient oncology services, and advice on end-of-life care.
Read More
Sunvozertinib Shows Activity, Tolerable Safety in EGFR Exon20 Insertion-Positive NSCLC
June 6th 2023Phase 2 results have placed a novel EGFR exon 20 insertion inhibitors in the realm of possibilities for future treatment of previously-treated non–small cell lung cancer with EGFR exon 20 insertions in the tumor tissue.
Read More
Datopotamab Deruxtecan/Pembrolizumab Combo Show Anti-tumor Activity in Advanced NSCLC
June 6th 2023New results from the TROPION-Lung02 trial highlight the potential of the antibody-drug conjugate datopotamab deruxtecan with pembrolizumab for patients with advanced non–small cell lung cancer.
Read More
Nivolumab/Ipilimumab Plus Chemotherapy as Frontline Therapy Shows Continued Efficacy in mNSCLC
June 5th 2023Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.
Read More
Following Prior Immunotherapy Resistance in Advanced PD-L1+ NSCLC Rilvegostomig Shows Promise
June 4th 2023Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.
Read More